tradingkey.logo
tradingkey.logo
Pesquisar

ImmuCell Corp

ICCC
Adicionar à lista de desejos
10.290USD
-0.710-6.45%
Fechamento 07/02, 13:00ETCotações atrasadas em 15 min
93.09MValor de mercado
PerdaP/L TTM

Mais detalhes de ImmuCell Corp Empresa

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).

Informações de ImmuCell Corp

Código da empresaICCC
Nome da EmpresaImmuCell Corp
Data de listagemMay 01, 1987
CEOte Boekhorst (Olivier)
Número de funcionários69
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 01
Endereço56 Evergreen Drive
CidadePORTLAND
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal04103
Telefone12078782770
Sitehttps://immucell.com/
Código da empresaICCC
Data de listagemMay 01, 1987
CEOte Boekhorst (Olivier)

Executivos da empresa ImmuCell Corp

Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
216.70K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
131.39K
-1.55%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--
Ms. Gloria J. Basse
Ms. Gloria J. Basse
Independent Director
Independent Director
--
--
Mr. Timothy C. Fiori
Mr. Timothy C. Fiori
Chief Financial Officer, Treasurer, Secretary, Director
Chief Financial Officer, Treasurer, Secretary, Director
--
--
Mr. Olivier te Boekhorst
Mr. Olivier te Boekhorst
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
216.70K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
131.39K
-1.55%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--

Perguntas frequentes

Quem são os cinco principais acionistas de ImmuCell Corp?

Os cinco principais acionistas de ImmuCell Corp são: Mr. Michael F. Brigham

Quantas instituições possuem ações da ImmuCell Corp (ICCC)?

Em 2026Q1, 48 instituições possuíam ações da ImmuCell Corp, com valor de mercado aproximado de 2.16M, representando 23.86% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 228934.00.

Qual é a maior fonte de receita da ImmuCell Corp?

Em 2026Q1, o segmento de negócios First Defense® product line gerou a maior receita para ImmuCell Corp, totalizando 27.45M e representando 99.29% da receita total.